New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens. 2021

Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia.

The rise in multidrug-resistant bacteria defines the need for identification of new antibacterial agents that are less prone to resistance acquisition. Compounds that simultaneously inhibit multiple bacterial targets are more likely to suppress the evolution of target-based resistance than monotargeting compounds. The structurally similar ATP binding sites of DNA gyrase and topoisomerase Ⅳ offer an opportunity to accomplish this goal. Here we present the design and structure-activity relationship analysis of balanced, low nanomolar inhibitors of bacterial DNA gyrase and topoisomerase IV that show potent antibacterial activities against the ESKAPE pathogens. For inhibitor 31c, a crystal structure in complex with Staphylococcus aureus DNA gyrase B was obtained that confirms the mode of action of these compounds. The best inhibitor, 31h, does not show any in vitro cytotoxicity and has excellent potency against Gram-positive (MICs: range, 0.0078-0.0625 μg/mL) and Gram-negative pathogens (MICs: range, 1-2 μg/mL). Furthermore, 31h inhibits GyrB mutants that can develop resistance to other drugs. Based on these data, we expect that structural derivatives of 31h will represent a step toward clinically efficacious multitargeting antimicrobials that are not impacted by existing antimicrobial resistance.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies

Related Publications

Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
March 2019, Expert opinion on therapeutic patents,
Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
July 2023, ACS omega,
Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
September 2020, Bioorganic chemistry,
Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
May 2013, Bioorganic & medicinal chemistry letters,
Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
February 2023, Pharmaceuticals (Basel, Switzerland),
Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
July 2016, The Journal of antimicrobial chemotherapy,
Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
July 2023, Future microbiology,
Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
November 2022, Bioorganic & medicinal chemistry,
Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
August 2017, Bioorganic & medicinal chemistry letters,
Martina Durcik, and Ákos Nyerges, and Žiga Skok, and Darja Gramec Skledar, and Jurij Trontelj, and Nace Zidar, and Janez Ilaš, and Anamarija Zega, and Cristina D Cruz, and Päivi Tammela, and Martin Welin, and Yengo R Kimbung, and Dorota Focht, and Ondřej Benek, and Tamás Révész, and Gábor Draskovits, and Petra Éva Szili, and Lejla Daruka, and Csaba Pál, and Danijel Kikelj, and Lucija Peterlin Mašič, and Tihomir Tomašič
January 2008, Methods in molecular medicine,
Copied contents to your clipboard!